Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
NCT02350712
Completed
The purpose of this study is to test a study drug called patritumab. Patritumab may work when combined with other medications that are approved in the UK for treating Squamous Cell Carcinoma of the Head and Neck (SCCHN), called cetuximab, cisplatin or carboplatin. It is hoped that patritumab may have some benefit in treating patients with cancer. This study will help identify how much patritumab can be given in combination with cetuximab, and cisplatin or carboplatin. This study will show how sa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2018
Locations: The Royal Marsden Hospital, Sutton, Surrey +2 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma
NCT02272816
Completed
This study evaluated the safety, efficacy and toxicity of carboplatin area under the curve (AUC)-10 in metastatic seminoma to see if, by using fluoro-deoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) to assess metabolic response, the number of patients requiring 4 cycles can be reduced. Carboplatin AUC-10 was given every 21 days. A PET-CT scan was carried out on day 17-21 of the first cycle. If the PET - CT scan showed a complete response patients received 3 cycles of... Read More
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
08/10/2018
Locations: Barts Health NHS Trust, London, Not set +1 locations
Conditions: Metastatic Seminoma
Register for Updates
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
NCT00276640
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy to see how well it works in treating patients with clinically or radiologically progressive low-grade gliomas.
Gender:
ALL
Ages:
Between 1 day and 18 years
Trial Updated:
04/19/2018
Locations: Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik, Wien, Not set +12 locations
Conditions: Primary Central Nervous System Neoplasms
Register for Updates
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
NCT01809210
Completed
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC. The study has been designed to allow an investigation of the optimal dose of selumetinib in combination with various standard first line double-platinum chemotherapy regimens. Initial assessment will be based on tolerability of selumetinib in combination with one or more selected regimens that are considered to be tole... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/12/2018
Locations: Research Site, Glasgow, Not set +3 locations
Conditions: Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Register for Updates
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
NCT01237678
Terminated
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2017
Locations: Arizona Cancer Center @ UMC North, Tucson, Arizona +47 locations
Conditions: Small Cell Lung Cancer
Register for Updates
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
NCT01015118
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/03/2017
Locations: 1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona +280 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Register for Updates
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
NCT00937560
Completed
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants received 6-8 3-week cycles of treatment with bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve (AUC) of 6 on day 1 of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/05/2017
Locations: Hospital Amaral Carvalho, Jau, SP +54 locations
Conditions: Ovarian Cancer
Register for Updates
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
NCT00136578
Completed
The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2017
Locations: GSK Investigational Site, Nashville, Tennessee +1 locations
Conditions: Solid Tumours
Register for Updates
Dose-finding Study in Platinum-Resistant Ovarian Cancer
NCT01653912
Completed
* Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer. * Safety and efficacy study of GSK2110183 administered in combination with carboplatin and paclitaxel to subjects with platinum-resistant ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/30/2017
Locations: Royal Brisbane and Women's Hospital, Herston, Queensland +9 locations
Conditions: Recurrent Platinum-resistant Ovarian Cancer
Register for Updates
Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers
NCT02423590
Unknown
This study is being carried out to see if a new drug called Apatorsen in combination with standard gemcitabine/carboplatin chemotherapy is effective in treating squamous cell lung cancer. This study is part of a research project for collecting information about the effectiveness and safety of Apatorsen when used with gemcitabine/carboplatin chemotherapy. The main purpose of this study is to see if Apatorsen, when combined with gemcitabine/carboplatin, is an effective treatment for squamous cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2017
Locations: Royal Cornwall Hospitals NHS Trust, Truro, Cornwall +19 locations
Conditions: Squamous Cell Lung Cancer
Register for Updates
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
NCT01493843
Completed
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Alabama Oncology, Birmingham, Alabama +119 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383148
Terminated
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG401... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +71 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates